Although degradable scaffolds are disappointing in cardiovascular disease, researchers believe that degradable stents may change the treatment of atherosclerotic diseases of the lower extremities. The five-year follow-up results of ABSORB BTK and the one-year follow-up results of DISAPEAR show a high percentage of target blood vessel revascularization-free.

Experts say that although large-scale randomized controlled clinical trials of Absorb degradable scaffolds have not been successful, it does not mean that BVS is dead or that companies in the industry should postpone future research. But experts also reminded that the way forward for BVS is full of challenges.